company background image
PTG

Poltreg WSE:PTG Stock Report

Last Price

zł43.60

Market Cap

zł203.3m

7D

-0.7%

1Y

n/a

Updated

23 May, 2022

Data

Company Financials +
PTG fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

PTG Stock Overview

Poltreg S.A., a biotechnology company, develops therapies for autoimmune diseases using T-regulatory cells.

Poltreg Competitors

 

 

 

 

 

 

 

 

 

 

 

 

Price History & Performance

Summary of all time highs, changes and price drops for Poltreg
Historical stock prices
Current Share Pricezł43.60
52 Week Highzł73.90
52 Week Lowzł40.00
Beta0
1 Month Change-9.92%
3 Month Change-26.10%
1 Year Changen/a
3 Year Changen/a
5 Year Changen/a
Change since IPO-29.67%

Recent News & Updates

Feb 24
Poltreg (WSE:PTG) Is In A Good Position To Deliver On Growth Plans

Poltreg (WSE:PTG) Is In A Good Position To Deliver On Growth Plans

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Shareholder Returns

PTGPL BiotechsPL Market
7D-0.7%-1.7%0.9%
1Yn/a-40.0%-15.6%

Return vs Industry: Insufficient data to determine how PTG performed against the Polish Biotechs industry.

Return vs Market: Insufficient data to determine how PTG performed against the Polish Market.

Price Volatility

Is PTG's price volatile compared to industry and market?
PTG volatility
PTG Average Weekly Movement5.9%
Biotechs Industry Average Movement8.7%
Market Average Movement7.7%
10% most volatile stocks in PL Market14.8%
10% least volatile stocks in PL Market5.1%

Stable Share Price: PTG is less volatile than 75% of Polish stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: PTG's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
n/a8n/ahttps://poltreg.tech

Poltreg S.A., a biotechnology company, develops therapies for autoimmune diseases using T-regulatory cells. It engages in the research and development of therapies for the treatment of type 1 diabetes in children and in multiple sclerosis. The company is based in Gdansk, Poland.

Poltreg Fundamentals Summary

How do Poltreg's earnings and revenue compare to its market cap?
PTG fundamental statistics
Market Capzł203.33m
Earnings (TTM)-zł3.74m
Revenue (TTM)zł1.10m

185.0x

P/S Ratio

-54.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
PTG income statement (TTM)
Revenuezł1.10m
Cost of Revenuezł282.00k
Gross Profitzł817.00k
Other Expenseszł4.56m
Earnings-zł3.74m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

May 27, 2022

Earnings per share (EPS)-0.80
Gross Margin74.34%
Net Profit Margin-340.13%
Debt/Equity Ratio0.03%

How did PTG perform over the long term?

See historical performance and comparison

Valuation

Is Poltreg undervalued compared to its fair value and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


1.97x

Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate PTG's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate PTG's fair value for valuation analysis.


Price To Earnings Ratio

PE vs Industry: PTG is unprofitable, so we can't compare its PE Ratio to the Polish Biotechs industry average.

PE vs Market: PTG is unprofitable, so we can't compare its PE Ratio to the Polish market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate PTG's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: PTG is good value based on its PB Ratio (2x) compared to the PL Biotechs industry average (4.5x).


Future Growth

How is Poltreg forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

Future Growth Score

2/6

Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


80.8%

Forecasted annual revenue growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if PTG's forecast earnings growth is above the savings rate (2.5%).

Earnings vs Market: Insufficient data to determine if PTG's earnings are forecast to grow faster than the Polish market

High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: PTG's revenue (80.8% per year) is forecast to grow faster than the Polish market (6% per year).

High Growth Revenue: PTG's revenue (80.8% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if PTG's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Poltreg performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-325.7%

Last years earnings growth

Earnings and Revenue History

Quality Earnings: PTG is currently unprofitable.

Growing Profit Margin: PTG is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if PTG's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare PTG's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PTG is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-6.2%).


Return on Equity

High ROE: PTG has a negative Return on Equity (-3.63%), as it is currently unprofitable.


Financial Health

How is Poltreg's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: PTG's short term assets (PLN106.0M) exceed its short term liabilities (PLN5.7M).

Long Term Liabilities: PTG's short term assets (PLN106.0M) exceed its long term liabilities (PLN436.0K).


Debt to Equity History and Analysis

Debt Level: PTG has more cash than its total debt.

Reducing Debt: Insufficient data to determine if PTG's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: PTG has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: PTG has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 45.8% each year


Dividend

What is Poltreg current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate PTG's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate PTG's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if PTG's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PTG's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as PTG has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?


CEO

Poltreg has no CEO, or we have no data on them.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: PTG only recently listed within the past 12 months.


Top Shareholders

Company Information

Poltreg S.A.'s employee growth, exchange listings and data sources


Key Information

  • Name: Poltreg S.A.
  • Ticker: PTG
  • Exchange: WSE
  • Founded: NaN
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: zł203.326m
  • Shares outstanding: 4.66m
  • Website: https://poltreg.tech

Number of Employees


Location

  • Poltreg S.A.
  • Waly Piastowskie 1 lok. 1508
  • Gdansk
  • 80-855
  • Poland

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/23 00:00
End of Day Share Price2022/05/23 00:00
Earnings2021/12/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.